Sage Group is attending BioEurope Spring 2023 from 20-23 March 2023! Please click here to setup a call with us in advance or book on the partnering sessions!

New York and London, July 28, 2021 - The Sage Group has announced that it advised Cancer Prevention Pharmaceuticals, Inc. (CPP), resulting in the North American licensing of its fixed dose combination drug Flynpovi for the treatment of familial adenomatous polyposis (FAP), an orphan disease which affects 25 to 30,000 individuals in the US and for which the product has received Fast Track and Orphan Drug designation Neither the identity of the licensee nor the terms of the lic

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (“medac”) to commercialize treosulfan, a bifunctional alkylating agent, in Canada.